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CD371 cell surface expression: a unique feature of
DUX4-rearranged acute lymphoblastic leukemia 
B-cell precursor acute lymphoblastic leukemia (B-ALL),
the most common childhood malignancy, comprises
genetically, biologically and clinically heterogeneous dis-
ease entities.1,2 Given the concepts of risk-adapted or tar-
geted therapies, their precise delineation is becoming
increasingly important.1-3 The recently discovered IGH-
DUX4 or, less commonly, ERG-DUX4 rearranged subtype
of B-ALL accounts for 5-7% of the cases and is character-
ized by the expression of C-terminally truncated DUX4
isoforms, a highly distinctive gene expression signature
and a profound deregulation of ERG.4-6 Somatic ERG dele-
tions, which occur in roughly half of DUX4+ patients,4,6
are indicative of a favorable outcome and attenuate the
negative prognostic effect of adverse factors such as
IKZF1 deletions alone7,8 or in combination with other
deletion events.9 Given that ERG deletions are secondary
events driven by the overexpression of DUX4,6 they
delineate only a subset of DUX4+ cases and it remains to
be determined whether only those patients with ERG
deletions or the entire cohort of DUX4+ patients has a
superior outcome. However, a reliable identification of
DUX4+ leukemia currently requires gene expression pro-
filing or next-generation sequencing approaches,4-6which
are not yet feasible either for large-scale screening studies
or in a diagnostic setting for many study centers. Herein
we show that expression of the cell surface antigen
CD371 (CLL-1), encoded by CLEC12A and easily
detectable by flow cytometry,10,11 is a unique feature of
DUX4-rearranged B-ALL and identifies virtually all
DUX4+ cases.
Our evaluation of the immunophenotype of DUX4+
leukemia provides solid evidence that CD371 cell surface
expression is a highly specific surrogate marker to identi-
fy this otherwise difficult to ascertain genetic subgroup.
This notion is based on the finding that of 46 DUX4+
cases, 42 showed strong and three weak CD371 antigen
expression (Table 1), while all other genetic subtypes
were basically negative (Online Supplementary Tables S1-
3).
In order to detect DUX4+ cases we performed RNA-
sequencing of two independent cohorts of patients with
childhood or young adolescent leukemia (Online
Supplementary Methods; Online Supplementary Tables S1
and S2). The Austrian cohort (cohort 1) consisted of 101
bone marrow samples from 92 patients (n=80 diagnostic,
n=3 relapse samples, n=9 diagnosis/relapse matched
pairs). It comprised mostly B-other cases (n=65) lacking
sentinel genetic alterations as well as representative cases
of all major genetic subtypes (Online Supplementary Table
S1). Initially, most samples were subjected to RNA-
sequencing without prior knowledge of their
immunophenotypic details, but later on nine more
CD371+ samples with unknown genetic subtype and
available material were sequenced. A second cohort
(cohort 2) from the Czech Republic consisted of 55 pri-
marily B-other cases, analyzed in parallel for CD371
expression (Online Supplementary Table S2).
DUX4+ samples were identified by the analysis of
DUX4 expression levels (Figure 1A), the presence of
DUX4 fusion transcripts (Online Supplementary Tables S1
and S2) and their distinctive gene expression profile4-6,12,13
(Online Supplementary Methods; Online Supplementary
Figure S1). Of 48 cases classified as DUX4+, 44 harbored
IGH-DUX4 and one a DUX4-ZNF384 fusion, while three
lacked any DUX4 fusion (Online Supplementary Tables S1
and S2); but all displayed the gene expression signature
typical of DUX4+ leukemia (Online Supplementary Figure
S1). As determined by single nucleotide polymorphism
array analysis (Online Supplementary Methods) and genom-
ic multiplex polymerase chain reaction,8 32% (15/47) and
65% (13/20) of the patients, respectively, showed 
ERG deletions (Online Supplementary Tables S1 and S2;
Online Supplementary Figure S2), confirming that with
either method they are detectable only in a subset of
DUX4+ cases.4,6 About one-third of DUX4+ cases displayed
IKZF1 deletions (Online Supplementary Methods; Online
Supplementary Tables S1 and S2; Online Supplementary
Figure S2), which is comparable to the frequency detected
in ERG-deleted leukemia.7,8
While in the ALL-BFM 2000 clinical trial ERG-deleted
patients were more frequently allocated to the intermedi-
ate-risk group and had a favorable outcome,8 in the ALL-
BFM 2009 study, as a consequence of more refined mini-
mal residual disease stratification, DUX4+ patients were
more commonly treated in the high-risk arm14 (Online
Supplementary Tables S1 and S2). However, to date, the
follow-up of the latter cohort of patients is still too short
to draw any conclusions on whether a poor initial treat-
ment response in DUX4+ leukemia eventually results in a
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Table 1. Summary of DUX4+ and CD371+ patients detected in the cohorts subjected to RNA-sequencing.
Patients                                                                 DUX4                               CD371 strong                                 CD371 weak
(n=119)*                                                             (n=48)#                                   (n=43)                                             (n=9)
CD371 strong                                                              91.3% (42/46)                                          −                                                               −
CD371 weak                                                                   6.5% (3/46)                                            −                                                               −
CD371 negative                                                             2.2% (1/46)                                            −                                                               −
DUX4+                                                                                      −                                          97.7% (42/43)                                           33.3% (3/9)
DUX4–                                                                                       −                                            2.3% (1/43)                                             66.7% (6/9)
high hyperdiploid                                                                −                                                     −                                                      22.2% (2/9)
BCR-ABL1                                                                              −                                                     −                                                      11.1% (1/9)
near haploid                                                                         −                                                     −                                                      11.1% (1/9)
B-other                                                                                  −                                            2.3% (1/43)                                             22.2% (2/9)
*Data were derived from 125 samples from 119 patients for whom both RNA-sequencing and CD371 data were available. #2 patients did not have material available for
immunophenotyping. 
poor outcome and whether DUX4+ patients might benefit
further from therapy intensification or should rather be
spared from additional cytotoxicity.
DUX4+ leukemia is characterized by high expression of
distinct genes including CLEC12A6,13 encoding the cell
surface protein CD371. Notably, in DUX4-rearranged
leukemia DUX4 binds to the CLEC12A locus, suggesting
a direct transcriptional regulation.6 CD371 is predomi-
nantly expressed on myeloid cells and, as a potential
myeloid cancer stem cell marker, is considered a target
for antibody-based or chimeric antigen receptor T-cell
therapies.11 Furthermore, CD371 expression is associated
with ‘switch’ ALL,10,14 which has a propensity to switch-
ing to monocyte-like cells upon treatment with corticos-
teroids.15
The previously reported overexpression of CLEC12A in
haematologica 2019; 104:e353
LETTERS TO THE EDITOR
Figure 1. Identification of DUX4-
positive leukemia. (A) The number
of reads that mapped to DUX4
cDNA (NM_001293798.2) per
million total mapped reads
assigned to RefSeq entries (RPM)
for cohort 1 (left panel) and cohort
2 (right panel) are shown. DUX4+
cases are represented in red;
cases with elevated DUX4 expres-
sion but lacking detectable IGH-
DUX4 fusion transcripts are repre-
sented in brown. (B) Boxplots
showing the expression levels of
CLEC12A depicted as log2-trans-
formed normalized counts calcu-
lated by DESeq2 in cohort 1 (101
samples from 92 patients) and
cohort 2 (55 patients) (left and
right panel, respectively). (C)
Representative FACS plots of pri-
mary bone marrow cells from
patients with B-cell acute lym-
phoblastic leukemia (B-ALL)
stained for CD371-APC or CD371-
PE; blast cells are depicted in red.
B-other, B-ALL cases lacking any
sentinel alteration; CRLF2, cases
with P2YR8-CRLF2 or IGH-CRLF2
rearrangement; DUX4, cases with
expression of DUX4; haploid,
masked near haploid; HD, high
hyperdiploid; iAMP21, intrachro-
mosomal amplification of chromo-
some 21; kinase-act, cases har-
boring a kinase activation fusion
gene; KMT2A, KMT2A fusion
gene; MEF2D, MEF2D fusion
gene; ZNF384, ZNF384 fusion
gene; SSC: side scatter; APC: allo-
phycocyanin; PE: phycoerythrin;
RNA-seq: RNA-sequencing.
A
B
C
DUX4+ leukemia6,13 was confirmed in both cohorts ana-
lyzed by RNA-sequencing (Figure 1B), and hence, we
analyzed whether this correlates with CD371 cell surface
antigen positivity. Immunophenotyping by flow cytome-
try and classification into strong or weak antigen expres-
sion of the respective samples with available material
was performed according to the AIEOP-BFM consensus
guidelines (Online Supplementary Methods).10 CD371
expression was determined using phycoerythrin- or allo-
phycocyanin-conjugated mouse anti-human CD371
(clone 50C1; BD Biosciences or BioLegend).
Of 46 DUX4+ cases with immunophenotypic data,
91.3% (42/46) were CD371strong, 6.5% (3/46) CD371weak
and 2.2% (1/46) CD371neg (Table 1; Figure 1C; Online
Supplementary Figure S2). The last case harbored the
exceptional DUX4-ZNF384 fusion but showed an expres-
sion signature similar to that of DUX4+ leukemia (Online
Supplementary Figure S1). Vice versa, 97.7% (42/43) of all
CD371strong cases were DUX4+ and only one single outlier
(2.3%; 1/43) did not show either a DUX4 or any other
fusion gene that might explain the phenotype.
In most of the nine samples classified as CD371weak
only a subfraction of leukemic blasts (10-38%) was anti-
gen positive (Figure 1C). These cases were genetically
more diverse and comprised three DUX4+, two high
hyperdiploid, one BCR-ABL1, one masked near haploid
and two B-other cases, one of which was only analyzed
at relapse (Table 1; Online Supplementary Tables S1 and
S2). There was no clear difference in the staining pattern
between CD371weak DUX4+ samples and those with other
genetic subtypes (Figure 1C).
To further substantiate the specificity of CD371 anti-
gen expression for DUX4+ leukemia, we genetically sub-
typed 258 consecutive cases from Austrian BFM cohorts
prospectively analyzed for CD371 expression (Online
Supplementary Methods; Online Supplementary Table S3).
Forty-eight of these patients, mostly DUX4+ and B-other
cases, overlapped with cohort 1. Of 14 CD371strong cases
all 12 analyzed by RNA-sequencing (no material was
available for 2) were classified as DUX4+. Conversely,
among 240 CD371neg cases a single DUX4+ case was
found, corresponding to the one with a DUX4-ZNF384
fusion. The few CD371weak samples again showed vari-
able genotypes (n=1 DUX4+; n=2 KMT2A-AFF1+; n=1
high hyperdiploid). Hence, in the rare cases of weak
CD371 expression, exclusion of the major genetic sub-
types is required to rule out false interpretation as DUX4+
leukemia.
Considering that KMT2A-rearranged leukemia shows
phenotypic heterogeneity with varying degrees of
myeloid-lineage-associated antigen expression and that
CD371 is primarily expressed on myeloid cells, an inter-
national prospective study is necessary to exclude occa-
sional CD371strong expression in this rare B-ALL entity.
CD2 antigen expression, previously described in 35-
45% of ERG-deleted cases,7,8 was strongly associated
with DUX4+ leukemia and present in roughly 75% of the
patients, while basically absent in all other genetic sub-
types (Online Supplementary Tables S1 and S2; Online
Supplementary Figure S2). The higher frequency of CD2+
cases is most likely attributable to an enrichment of our
DUX4+ cohort for ‘switch’ ALL cases commonly express-
ing CD371 and CD2.14,15 In addition, the classification of
the European Group for Immunophenotyping of
Leukemias (EGIL) applied in the two previous studies7,8
and the AIEOP-BFM consensus guidelines (Online
Supplementary Methods)10 consider cutoffs of 20% and
10%, respectively, to call a sample positive. Except for
one single case with an unknown genetic subtype, all
CD2 and CD371 double-positive cases were DUX4+.
Accordingly, CD2 expression alone will detect only a
proportion of DUX4+ cases but is also a strong indicator
and in particular in combination with CD371 antigen
expression may further underpin DUX4 positivity.
Taken together our data provide compelling evidence
that strong CD371 antigen expression in B-ALL is
pathognomonic of DUX4+ leukemia. The remarkable
finding that one single cell surface protein simply ana-
lyzed by flow cytometry may serve as a surrogate marker
to identify DUX4+ leukemia will considerably facilitate
the detection and further investigation of this disease
entity as well as the determination of the prognostic rel-
evance of DUX4 positivity rather than ERG deletions
alone,7,8 which are present in only a subset of the cases.4,6
Although the international BFM-FLOW network does
not consider immunophenotyping as a general gateway
for genetic assessments,10 we explicitly recommend the
implementation of CD371 staining in the upfront flow
cytometry-based analysis of childhood and adolescent B-
cell leukemia for the identification of the DUX4+ subtype.
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